Portfolio Manager's Biotech Watchlist Picks for 2018
Source: Streetwise Reports  (1/2/18)
StoneCastle Investment Management has a high-growth fund that invests wherever it finds opportunities, and it is bullish on healthcare. In this interview with The Life Sciences Report, portfolio manager Bruce Campbell highlights four companies that he is putting on Streetwise Reports' 2018 Biotech Watchlist.
More >

2017: A Year of Triple Digit Stock Performance
Source: Streetwise Reports  (12/28/17)
As stock indexes in the U.S. hit record highs in 2017, we take a look at some of the best performers profiled by Streetwise Reports in the last year, some of which have seen triple digit increases. More >

Biotech's Shares 'Undervalued' and Positioned for 'Long-Term Upside Potential'
Source: Streetwise Reports  (12/27/17)
Zacks Small-Cap Research analyst John Vandermosten reviewed the Q2 FY18 financial results for this epigenetics firm, which is moving forward with a Phase 3 trial targeting heart disease.
More >

Immunotherapy Firm Gets Green Light for Pivotal Trial From FDA
Source: Streetwise Reports  (12/27/17)
Jason Kolbert, an analyst with Maxim Group, described the study, which enables this biotech's device to be used in patients undergoing heart surgery and will measure its effectiveness in reducing a common post-surgical side effect.
More >

'Exciting' Collaborations Possible for Biotech's 'Flexible' Platform
Source: Streetwise Reports  (12/20/17)
Zacks Small-Cap Research's John Vandermosten discussed the potential for this immunotherapy firm's RNAi compounds in oncology. More >

Biotech Receives 'Major Endorsement from World-Leading Pharma Company'
Source: Streetwise Reports  (12/20/17)
David Kideckel, an analyst with Beacon Securities Ltd., relayed news from this firm's recent annual meeting, including a private placement with a large pharma and an update on the Phase 3 trial of its lead therapy. More >

Updates from ASH Reinforce Analyst's Big Price Target Potential
Source: Streetwise Reports  (12/20/17)
Andrew Fein, an analyst with H.C. Wainwright & Co., discussed the implications of this biopharmaceutical's recently announced data, which support his "bullish" outlook for the firm's candidate in chronic graft versus host disease.
More >

Cannabis Biotech Stock Starting to Advance Again
Source: Clive Maund for Streetwise Reports  (12/15/17)
A technical analysis by Clive Maund on CliveMaund.com has a Buy on this cannabis biotech stock. More >

'The Market Gets it Wrong, Again'; Analyst Raises Target Price on Biotech
Source: Streetwise Reports  (12/13/17)
Ed Arce, an analyst with H.C. Wainwright & Co., explained the positive elements of this drug developer's recently released clinical trial data and why they did not warrant the market reaction they got.
More >

A New Breed of Regenerative Therapy Companies Taking Hold
Source: Hunter Diamond, CFA for Streetwise Reports  (12/7/17)
A regenerative therapy company with expertise in both cell therapy development and manufacturing, and a potential treatment for diabetes, differentiates this company, says Hunter Diamond, CFA, CEO of Diamond Equity Research. More >

Biotech Delivers 'Great' Phase 2 Data in NASH
Source: John McCamant for Streetwise Reports  (12/7/17)
John McCamant of the Medical Technology Stock Letter raised his target price on this company given the earning potential of a once-a-day oral treatment for liver disease in what could be a $35 billion market.
More >

Immuno-Oncology Candidate Yields 'Impressive' Early Clinical Results
Source: Streetwise Reports  (12/6/17)
This biotech reported positive results in a Phase 1b trial for its ovarian cancer immuno-oncology drug-delivery candidate, prompting increases in share price targets from a pair of analysts. More >

Coverage Initiated on 'One of the Most Undervalued Biotech Companies in Canada'
Source: Streetwise Reports  (12/6/17)
David Kideckel, an analyst with Beacon Securities Ltd., explained the investment thesis for this clinical-stage life sciences firm. More >

Biotech Advances Potential 'Billion-Dollar Drug' with New Trial Launch in China
Source: Streetwise Reports  (12/5/17)
Maxim Group analyst Jason Kolbert discussed what the launch of a clinical trial in China means for this developer of immuno-oncology therapies.
More >

Drug in Combination with Merck's Blockbuster Keytruda Nearly Doubles Response Rate
Source: Michael Sheikh for Streetwise Reports  (12/4/17)
Michael Sheikh, the founder of Falcon Strategic Research, delves into a biotech company whose trial results he believes could fuel takeover speculation. More >

Potential Alzheimer's Therapies Focus on Early Intervention
Source: Streetwise Reports  (11/30/17)
After attending a conference on the latest in development of Alzheimer's disease treatments, Andrew Fein, an analyst with H.C. Wainwright & Co., provided an industry update. More >

Analyst's 'Top Pick' Advances Vaccine Candidates
Source: Streetwise Reports  (11/21/17)
Douglas Loe, an analyst with Echelon Wealth Partners, provided an update on this biotech's platform pipeline targeting ovarian and blood cancers, as well as respiratory syncytial virus. More >

Stock Price Jump Reflects Biotech's Active October
Source: Streetwise Reports  (11/20/17)
This immunotherapy firm's stock recently doubled its Nov. 7 price following lots of news, including a clinical data release, a trial launch and an executive appointment.
More >

Maxim's Target Price on Biotech Makes It More Than a Tenbagger
Source: Streetwise Reports  (11/20/17)
Jason Kolbert, an analyst with Maxim Group, provided an update on this biopharmaceutical firm's two recently acquired oncology assets.
More >

'Hot' Alzheimer's Market is Promising for Biotech with 'Novel' Drug Candidate
Source: Streetwise Reports  (11/20/17)
André Uddin, an analyst with Mackie Research Capital Corp., summarized the quarterly financial results and anticipated catalysts for this Alzheimer's drug developer.
More >

Biotech's Target Price Increased as Shares 'Deeply Undervalued'
Source: Streetwise Reports  (11/15/17)
Wedbush analyst Robert Driscoll provided an update on the lead asset of this drug developer targeting cancer.
More >

Biotech Targets 'Blockbuster' Markets; Less-Addictive Opioid Painkiller Set for FDA Filing
Source: John McCamant for Streetwise Reports  (11/15/17)
Medical Technology Stock Letter editor John McCamant outlines the reasons behind the buy rating and target price increases for a company that, in addition to developing an alternative to addictive opioids for pain relief, has candidates targeting multiple immune disorders and cancer.
More >

Analyst Says Biotech Share Price Could Potentially 'Double'
Source: Streetwise Reports  (11/13/17)
Analyst Grant Zeng of Zacks Small Cap Research examines what transpired with this biopharmaceutical company during Q3/17. More >

Biotech with Solid Pipeline and 'Solid Partnership Outlook'
Source: Streetwise Reports  (11/13/17)
Analyst Kevin DeGeeter, with Ladenburg Thalmann, relayed the highlights from his recent meeting with this company's management team about near-term clinical news and pipeline plans.
More >

Biotech Reports Positive Topline Data; Biologics License Application in Progress
Source: Streetwise Reports  (11/6/17)
Ram Selvaraju, an analyst with H.C. Wainwright & Co., reviewed the recent clinical trial results released by this developer of cell therapies targeting oncology and orphan indications.
More >